Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Urology
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
•
Primary Care
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Related Questions
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
Do you have to extend treatment for acute Lyme disease if a patient is on high dose steroids for another indication?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
